Ep. 40: Acute Low Back Pain Guideline: A Clinician's Perspective

Episode Summary:Welcome back to the Pain Matters podcast, where Dr. Sudheer Potru, DO, alongside Dr. Mustafa Broachwala, DO, delves into crucial topics on acute low back pain guidelines. Featuring insights from Dr. Jessica Oswald, MD, MPH and Dr. Devin Kansagara, MD, FACP, this episode focuses on the implications of FDA-funded guidelines, co-sponsored by the American Academy of Pain Medicine. This expert panel discusses the nuances of managing acute low back pain, emphasizing evidence-based practices to improve patient care.Throughout the episode, Dr. Oswald and Dr. Kansagara explore the guidelines’ perspectives on imaging, opioids, and alternative therapies. Discussing the common tendency to order imaging tests for low back pain, the conversation shifts to effective patient communication and strategies for reducing unnecessary imaging. They also address opioid use, highlighting its role as a third-line option and discussing the importance of evaluating individual patient needs to optimize function without escalating risks. The episode also emphasizes non-pharmacological interventions, such as early physical therapy, and overcoming challenges related to access bottlenecks.Key Takeaways:Guideline Applicability: Emphasizing the acute stage, the guidelines apply to pain lasting less than six weeks.Imaging Insights: Many clinicians still rely heavily on imaging for acute low back pain despite evidence showing limited benefit. Patient communication is crucial in managing expectations.Opioid Recommendations: Reserved as a third-line treatment, opioids are not usually recommended for acute low back pain due to risks outweighing benefits in most cases.Non-Pharmacological Therapies: Early engagement in physical therapy and alternative therapies can enhance long-term recovery, highlighting the importance of patient education and movement.Epidural Injections and Controversies: The discussion points out the limited evidence for epidural steroid injections, prompting nuances in clinical decision-making amid evidence shortages.